Vitamin D Receptor Polymorphism and Breast Cancer
Author Information
Author(s): Alimirah Fatouma, Peng Xinjian, Murillo Genoveva, Mehta Rajendra G.
Primary Institution: Illinois Institute of Technology
Hypothesis
The FokI vitamin D receptor polymorphism affects breast cancer cell response to vitamin D treatment.
Conclusion
The VDRff genotype may contribute to more aggressive breast cancer, while VDRFF cells respond better to vitamin D treatment.
Supporting Evidence
- VDRFF cells showed 60% growth inhibition in response to vitamin D compared to 28% in VDRff cells.
- CYP24A1 mRNA was 1.8 times higher in VDRFF cells than in VDRff cells after vitamin D treatment.
- Estrogen receptor-α expression was downregulated by 62% in VDRFF cells compared to 25% in VDRff cells.
Takeaway
Some versions of a vitamin D receptor can make breast cancer cells grow faster, while others help the cells respond better to vitamin D treatment.
Methodology
MCF-7 breast cancer cell lines were established and treated with vitamin D to assess growth inhibition and gene expression.
Potential Biases
Potential selection bias in cell line characteristics and responses.
Limitations
The study may not account for all genetic and environmental factors influencing breast cancer risk.
Statistical Information
P-Value
p<0.01
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website